AI Terminal
Haleon PLC
Director's Dealing • Jun 3, 2025
5111_dirs_2025-06-03_012af141-6b52-4a29-acbe-09a580eeccc9.html
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2745L
Haleon PLC
03 June 2025
Haleon plc : Director/PDMR Shareholding
3 June 2025: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by Persons Discharging Managerial Responsibilities ("PDMRs").
On 2 June 2025, Ed Petter, Chief Corporate Affairs Officer, received the vesting of the first tranche of an award of Haleon Ordinary Shares under the Haleon Share Value Plan. The award was granted as part of his remuneration arrangements upon joining Haleon, to compensate for forfeited incentives from his previous employment.
The award is subject to malus and clawback provisions.
Further details are set out in the below notification, made in accordance with the requirements of The UK Market Abuse Regulations.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | ||||||
| a) | Name | Ed Petter | |||||
| 2 | Reason for the notification | ||||||
| a) | Position/status | Chief Corporate Affairs Officer | |||||
| b) | Initial notification /Amendment | Initial Notification | |||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||
| a) | Name | Haleon plc | |||||
| b) | LEI | 549300PSB3WWEODCUP19 | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | |||||
| Identification code | GB00BMX86B70 | ||||||
| b) | Nature of the transaction | Acquisition of Ordinary Shares in respect of the first vesting of the Haleon plc Share Value Plan (Buyout award). | |||||
| c) | Price(s) and volume(s) | ||||||
| Price(s) | Volume(s) | ||||||
| Nil | 51,584 | ||||||
| d) | Aggregated information | ||||||
| - Aggregated volume | N/A | ||||||
| - Price | |||||||
| e) | Date of the transaction | 2 June 2025 | |||||
| f) | Place of the transaction | Outside a trading venue | |||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of £0.01 each | |||||
| Identification code | GB00BMX86B70 | ||||||
| b) | Nature of the transaction | Automatic disposal of Ordinary Shares resulting from Haleon plc Share Value Plan (Buyout award) vesting to cover tax liabilities. | |||||
| c) | Price(s) and volume(s) | ||||||
| Price(s) | Volume(s) | ||||||
| £ 4.134623 | 24,305.243108 | ||||||
| d) | Aggregated information | ||||||
| - Aggregated volume | N/A | ||||||
| - Price | |||||||
| e) | Date of the transaction | 2 June 2025 | |||||
| f) | Place of the transaction | London Stock Exchange (XLON) | |||||
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHBSGDLBUGDGUX